The June 4, 2026 paper reports no results because BMJ Open labels it a protocol for a future phase 2 double-blind trial. It describes planned testing of oral probiotics plus a topical secretome, a liquid applied to skin, for acne vulgaris. Acne vulgaris is common acne with pimples, blackheads and inflamed spots. The ClinicalTrials.gov description notes it affects over 85% of people at some point and often involves prolonged antibiotics.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the future trial plans to test
- Who may care about this approach
- What safety information says about probiotics
- What to watch on acne-prone skin
What the future trial plans to test
The protocol plans four parallel arms. Each arm adds an oral probiotic or placebo and a topical secretome or placebo to standard acne therapy. BMJ Open presents this design to test clinical outcomes and microbiome restoration in the trial protocol.
The ICH GCP registry record mirrors the same four combinations with HEXBIO probiotic and secretome versus placebos. Planned measures include lesion counts, GAGS scores, IGA grades, microbiome changes and adverse events. Those results do not yet exist because the publication covers methods only.
Who may care about this approach
The relevant group is adolescents and adults with acne vulgaris. Many readers with acne-prone skin already use daily cleansers, retinoids, benzoyl peroxide or prescribed antibiotics. A combined gut-and-skin approach can sound appealing when breakouts persist.
The protocol does not offer a current treatment choice. It defines a research question about adding probiotics and secretome to standard therapy. Readers deciding today still need proven care, not trial methods.
What safety information says about probiotics
The U.S. NCCIH states probiotics generally cause only minor side effects in healthy people. It also reports severe or fatal infections in premature infants, with an FDA warning to clinicians about that risk, in the NCCIH safety summary.
NCCIH adds that detailed safety study remains rare. Data on how often harms occur and how severe they become are lacking. Risk runs higher for people who are seriously ill or immunocompromised.
What to watch on acne-prone skin
A dermatology review notes FDA has approved no topical probiotic as a drug. It also notes no regulation specific to topical probiotics exists, leaving safety and efficacy claims unverified for acne-prone skin, according to the dermatology review.
Dermatologist guidance summarized by AAD supports staying with guideline-based care rather than swapping in unproven probiotic or secretome topicals, described in the AAD guidance summary. Contact a dermatologist promptly for: Keep using proven care and report the product name, start date and symptoms at that visit.
- burning or stinging that persists after use
- new redness, itching, swelling or rash
- signs of allergy or worsening acne
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Safety and Skin-Reaction Questions for People With Acne-Prone Skin
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Safety and Skin-Reaction Questions for People With Acne-Prone Skin
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Safety and Skin-Reaction Questions for People With Acne-Prone Skin